

application directed to the broader embodiments of the present application. Thus, these changes to the claims should be made without prejudice as to the new application.

With regard to the rejections of claims 18-29 under 35 USC § 112, first paragraph, on enablement and written description grounds, these rejections have been overcome by the cancellation of claims 19-24 and 29, and the changes to claim 18. As noted above, the present claims have been amended to direct to just the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5 which the Examiner has indicated to be allowable. Thus, in light of these changes, these rejections can no longer be sustained and should be withdrawn.

With regard to the rejection of claims 18-28 under 35 USC § 102(b) as being anticipated by Bixler et al. (USP 5,785,973), this rejection has also been overcome by the cancellation of claims 19-24, and the changes to claim 18. Since claim 18 and claims 25-28 and 30 which depend therefrom, have been amended to incorporate the subject matter of non-rejected claim 29, this rejection also cannot be sustained and should be withdrawn.

With regard to non-elected claims 15 and 16, since these claims are directed to a method of using the allowable compounds for preventing or treating an allergy or a disease of allergic origin, it is respectfully requested that these claims be rejoined under *In re Ochiai* and allowed along with the elected claims.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Also attached is the formalized and executed Rule 1.132 Declaration based on the draft Declaration previous submitted with our Amendment of May 2, 2002. Please review and enter this executed Rule 1.132 Declaration into the application file.

In view of the foregoing amendments and remarks, it is respectfully submitted that the Application is now in condition for allowance. Such action is thus respectfully solicited.

Respectfully submitted,

Jean-Marie SAINT-REMY et al.

By: 

Lee Cheng

Registration No. 40,949

Attorney for Applicants

LC/gtg
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 17, 2002

3

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 18 has been amended as follows.

18. (Twice Amended) An isolated compound [for preventing or treating an allergy, said compound] consisting of [(a) at least one allergen antigenic determinant which is recognised by a B cell or an antibody secreted by a B cell of a non-atopic individual to said allergen and (b) at least one antigenic determinant of an antigen different from said allergen which triggers T cell activation, wherein said allergen is Der pI and Der pII of house dust mite *Dermatophagoides pteronyssinus*] one of the following amino acid sequences selected from the group consisting of SEO ID NO. 1, SEO ID NO. 3, SEO ID NO. 4 and SEO ID NO. 5.

E